
News|Articles|January 10, 2013
Canagliflozin may not be good for the heart, FDA says
Canagliflozin (Janssen Research & Development), developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, raised the level of bad cholesterol in patients during clinical trials and may post heart risks, according to FDA and reported by Reuters.
Advertisement
dagfgaf
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
A conversation with Tiffany Phung, Pharm.D., CSP, about how patient outcomes drive specialty pharmacy strategy
3
The sleep doctor who lives with a disorder he treats
4
FAQ: What health plans need to know about Medicare's GLP-1 Bridge program ahead of open enrollment
5





















